Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells

M. R. Bishop, J. D. Jackson, B. O'Kane-Murphy, K. Schmit-Pokorny, Julie Marie Vose, Philip Jay Bierman, Phyllis Irene Warkentin, James Olen Armitage, L. Garrison, A. Kessinger

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: Mobilization of peripheral-blood cells (PBC) with cytokines alone results in rapid hematopoietic recovery and avoids the potential morbidity associated with mobilization by chemotherapy. PIXY321, a fusion protein that consists of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), has enhanced hematopoietic colony-forming activity as compared with individual or equimolar combinations of the two cytokines. A phase I trial of PIXY321 for mobilization of PBC in patients with malignant lymphoma was performed. Patients and Methods: Thirteen patients with malignant lymphoma who were eligible for high-dose therapy (HDT) were enrolled onto the trial. All patients were ineligible for autologous bone marrow transplantation due to overt metastotic disease in the marrow or to severe marrow hypocellularity. PIXY321 was administered at three dose levels of 250, 500, and 750 μg/m2/d by continuous infusion until completion of PBC collections. Collections were initiated when the WBC count was greater than 10 x 109/L or 4 days after the initiation of PIXY321, whichever came first. Collections were continued until a minimum of 6.5 x 108 mononuclear cells (MNC)/kg patient weight were obtained. Results: PIXY321 was generally well tolerated. Side effects associated with PIXY321 administration did not exceed grade 2 and included fever (85%), chills/sweats (54%), myalgias (38%), fatigue (31%), nausea/vomiting (31%), headache (31%), edema (23%), and rhinorrhea (23%). The median numbers of colony-forming units-granulocyte/macrophage (CPU-GM) in the graft products for the three dose levels were 0.31, 2.94, and 2.88 x 104/kg, respectively; the median numbers of burst-forming units-erythroid (BFU-e) were 0.20, 6.94, and 12.78 x 104/kg, and the median numbers of CD34+ cells were 2.30, 0.74, and 0.39 x 106/kg. Following transplantation, the median times to an absolute neutrophil count (ANC) > 0.5 x 109/L were 12, 15, and 12 days, respectively, and the median times to platelet transfusion independence were 30, 19, and 15 days. Conclusion: PIXY321 can be safely administered and effectively mobilizes PBC in patients with bone marrow defects. PlXY321-mobilized PBC autotransplants result in rapid and sustained hematopoietic recovery.

Original languageEnglish (US)
Pages (from-to)2521-2526
Number of pages6
JournalJournal of Clinical Oncology
Volume14
Issue number9
DOIs
StatePublished - Jan 1 1996

Fingerprint

Blood Cells
Bone Marrow
Lymphoma
Cytokines
Platelet Transfusion
Chills
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Sweat
Autologous Transplantation
Interleukin-3
Myalgia
Autografts
Granulocyte-Macrophage Colony-Stimulating Factor
Bone Marrow Transplantation
Nausea
Vomiting
Fatigue
Headache
recombinant PIXY321 fusion protein

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. / Bishop, M. R.; Jackson, J. D.; O'Kane-Murphy, B.; Schmit-Pokorny, K.; Vose, Julie Marie; Bierman, Philip Jay; Warkentin, Phyllis Irene; Armitage, James Olen; Garrison, L.; Kessinger, A.

In: Journal of Clinical Oncology, Vol. 14, No. 9, 01.01.1996, p. 2521-2526.

Research output: Contribution to journalArticle

Bishop, M. R. ; Jackson, J. D. ; O'Kane-Murphy, B. ; Schmit-Pokorny, K. ; Vose, Julie Marie ; Bierman, Philip Jay ; Warkentin, Phyllis Irene ; Armitage, James Olen ; Garrison, L. ; Kessinger, A. / Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 9. pp. 2521-2526.
@article{16a780861c7649f5bd7f7f0d51e88f1c,
title = "Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells",
abstract = "Purpose: Mobilization of peripheral-blood cells (PBC) with cytokines alone results in rapid hematopoietic recovery and avoids the potential morbidity associated with mobilization by chemotherapy. PIXY321, a fusion protein that consists of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), has enhanced hematopoietic colony-forming activity as compared with individual or equimolar combinations of the two cytokines. A phase I trial of PIXY321 for mobilization of PBC in patients with malignant lymphoma was performed. Patients and Methods: Thirteen patients with malignant lymphoma who were eligible for high-dose therapy (HDT) were enrolled onto the trial. All patients were ineligible for autologous bone marrow transplantation due to overt metastotic disease in the marrow or to severe marrow hypocellularity. PIXY321 was administered at three dose levels of 250, 500, and 750 μg/m2/d by continuous infusion until completion of PBC collections. Collections were initiated when the WBC count was greater than 10 x 109/L or 4 days after the initiation of PIXY321, whichever came first. Collections were continued until a minimum of 6.5 x 108 mononuclear cells (MNC)/kg patient weight were obtained. Results: PIXY321 was generally well tolerated. Side effects associated with PIXY321 administration did not exceed grade 2 and included fever (85{\%}), chills/sweats (54{\%}), myalgias (38{\%}), fatigue (31{\%}), nausea/vomiting (31{\%}), headache (31{\%}), edema (23{\%}), and rhinorrhea (23{\%}). The median numbers of colony-forming units-granulocyte/macrophage (CPU-GM) in the graft products for the three dose levels were 0.31, 2.94, and 2.88 x 104/kg, respectively; the median numbers of burst-forming units-erythroid (BFU-e) were 0.20, 6.94, and 12.78 x 104/kg, and the median numbers of CD34+ cells were 2.30, 0.74, and 0.39 x 106/kg. Following transplantation, the median times to an absolute neutrophil count (ANC) > 0.5 x 109/L were 12, 15, and 12 days, respectively, and the median times to platelet transfusion independence were 30, 19, and 15 days. Conclusion: PIXY321 can be safely administered and effectively mobilizes PBC in patients with bone marrow defects. PlXY321-mobilized PBC autotransplants result in rapid and sustained hematopoietic recovery.",
author = "Bishop, {M. R.} and Jackson, {J. D.} and B. O'Kane-Murphy and K. Schmit-Pokorny and Vose, {Julie Marie} and Bierman, {Philip Jay} and Warkentin, {Phyllis Irene} and Armitage, {James Olen} and L. Garrison and A. Kessinger",
year = "1996",
month = "1",
day = "1",
doi = "10.1200/JCO.1996.14.9.2521",
language = "English (US)",
volume = "14",
pages = "2521--2526",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells

AU - Bishop, M. R.

AU - Jackson, J. D.

AU - O'Kane-Murphy, B.

AU - Schmit-Pokorny, K.

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Warkentin, Phyllis Irene

AU - Armitage, James Olen

AU - Garrison, L.

AU - Kessinger, A.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Purpose: Mobilization of peripheral-blood cells (PBC) with cytokines alone results in rapid hematopoietic recovery and avoids the potential morbidity associated with mobilization by chemotherapy. PIXY321, a fusion protein that consists of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), has enhanced hematopoietic colony-forming activity as compared with individual or equimolar combinations of the two cytokines. A phase I trial of PIXY321 for mobilization of PBC in patients with malignant lymphoma was performed. Patients and Methods: Thirteen patients with malignant lymphoma who were eligible for high-dose therapy (HDT) were enrolled onto the trial. All patients were ineligible for autologous bone marrow transplantation due to overt metastotic disease in the marrow or to severe marrow hypocellularity. PIXY321 was administered at three dose levels of 250, 500, and 750 μg/m2/d by continuous infusion until completion of PBC collections. Collections were initiated when the WBC count was greater than 10 x 109/L or 4 days after the initiation of PIXY321, whichever came first. Collections were continued until a minimum of 6.5 x 108 mononuclear cells (MNC)/kg patient weight were obtained. Results: PIXY321 was generally well tolerated. Side effects associated with PIXY321 administration did not exceed grade 2 and included fever (85%), chills/sweats (54%), myalgias (38%), fatigue (31%), nausea/vomiting (31%), headache (31%), edema (23%), and rhinorrhea (23%). The median numbers of colony-forming units-granulocyte/macrophage (CPU-GM) in the graft products for the three dose levels were 0.31, 2.94, and 2.88 x 104/kg, respectively; the median numbers of burst-forming units-erythroid (BFU-e) were 0.20, 6.94, and 12.78 x 104/kg, and the median numbers of CD34+ cells were 2.30, 0.74, and 0.39 x 106/kg. Following transplantation, the median times to an absolute neutrophil count (ANC) > 0.5 x 109/L were 12, 15, and 12 days, respectively, and the median times to platelet transfusion independence were 30, 19, and 15 days. Conclusion: PIXY321 can be safely administered and effectively mobilizes PBC in patients with bone marrow defects. PlXY321-mobilized PBC autotransplants result in rapid and sustained hematopoietic recovery.

AB - Purpose: Mobilization of peripheral-blood cells (PBC) with cytokines alone results in rapid hematopoietic recovery and avoids the potential morbidity associated with mobilization by chemotherapy. PIXY321, a fusion protein that consists of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), has enhanced hematopoietic colony-forming activity as compared with individual or equimolar combinations of the two cytokines. A phase I trial of PIXY321 for mobilization of PBC in patients with malignant lymphoma was performed. Patients and Methods: Thirteen patients with malignant lymphoma who were eligible for high-dose therapy (HDT) were enrolled onto the trial. All patients were ineligible for autologous bone marrow transplantation due to overt metastotic disease in the marrow or to severe marrow hypocellularity. PIXY321 was administered at three dose levels of 250, 500, and 750 μg/m2/d by continuous infusion until completion of PBC collections. Collections were initiated when the WBC count was greater than 10 x 109/L or 4 days after the initiation of PIXY321, whichever came first. Collections were continued until a minimum of 6.5 x 108 mononuclear cells (MNC)/kg patient weight were obtained. Results: PIXY321 was generally well tolerated. Side effects associated with PIXY321 administration did not exceed grade 2 and included fever (85%), chills/sweats (54%), myalgias (38%), fatigue (31%), nausea/vomiting (31%), headache (31%), edema (23%), and rhinorrhea (23%). The median numbers of colony-forming units-granulocyte/macrophage (CPU-GM) in the graft products for the three dose levels were 0.31, 2.94, and 2.88 x 104/kg, respectively; the median numbers of burst-forming units-erythroid (BFU-e) were 0.20, 6.94, and 12.78 x 104/kg, and the median numbers of CD34+ cells were 2.30, 0.74, and 0.39 x 106/kg. Following transplantation, the median times to an absolute neutrophil count (ANC) > 0.5 x 109/L were 12, 15, and 12 days, respectively, and the median times to platelet transfusion independence were 30, 19, and 15 days. Conclusion: PIXY321 can be safely administered and effectively mobilizes PBC in patients with bone marrow defects. PlXY321-mobilized PBC autotransplants result in rapid and sustained hematopoietic recovery.

UR - http://www.scopus.com/inward/record.url?scp=9544240331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9544240331&partnerID=8YFLogxK

U2 - 10.1200/JCO.1996.14.9.2521

DO - 10.1200/JCO.1996.14.9.2521

M3 - Article

C2 - 8823331

AN - SCOPUS:9544240331

VL - 14

SP - 2521

EP - 2526

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -